Clinical Trial Search

Primary: Percentage of Participants With Verified Prescription Contraceptive Use at the 6-month Assessment — 5; 14; 23 Participants — p=<.001

Primary: Contraceptive Acceptability and Use of Contraceptives During the 6-month Follow-up — 121; 86 participants

Primary: Continuation Rates — 82; 78; 83 participants

Primary: Contraceptive Continuation — 201; 174; 154; 118 Participants — p=0.46

Primary: Number of Participants Choosing Each Hormonal Contraceptive Method Before and After Counseling — 1207; 1199; 60; 131 Participants — p=0.705

Primary: Decisional Conflict Scale Score — 15; 10; 0; 0 score on a scale

Primary: Unintended Pregnancy — 46; 25 Participants

Primary: Number of Participants Using an Effective Contraceptive Method 6 Weeks After Abortion — 55; 55 Participants

Primary: Number of Participants With Implant Continuation — 219; 225 Participants

Primary: Number of Participants Who Continued to Breastfeed at 6 Months — 15; 14; 8; 9 participants

Primary: Number of Subjects With Pregnancy Outcomes to Measure Contraceptive Efficacy — 100 Participants

Primary: Contraceptive Method Discontinuation — 300; 62; 142 Participants

Primary: Percentage of Participants Who Appropriately Self-selected DR-104 (Plan B® 1.5) When Dispensed Under Simulated Over-the-counter (OTC) Conditions — 90.1 percentage of…

Primary: Number of Participants With Ovulation With Implant-alone — 7; 0 Participants

Primary: Time to Lactogenesis Stage II — 64.3; 65.2 hours — p=<0.05

Primary: Percent of HIV Target Immune Cells Within Female Genital Mucosa and Blood — 26.6; 22.8; 16.9; 22.4 percentage of HIV target immune cells

Primary: Feasibility of Application — 4.47; 4.52; 4.16; 4.26 units on a scale

Primary: Number of Premenopausal Women With Overweight/Obesity Who Initiated a COC vs. Continued NHC Use, Enrolled and Remained in This Study, and Completed Outcome Measures — 9…

Primary: Change From Baseline in Insulin Sensitivity — -1.91; -5.63 min ^ -1 / mIU / L

Primary: Use of an Effective Method of Contraception at 6 Months After Requesting Emergency Contraception — 9; 13 participants

Primary: Overall Satisfaction Rate at 18 Months (Last Observation Carried Forward, LOCF) — 82.1; 81.9 Percentage of participants

Primary: Number of Participants With Follicle Rupture — 1; 9 Participants

Primary: Changes in Insulin Sensitivity Associated With Oral Contraceptive (OC) Use Compared Among (1) Obese Women and (2) Lean Women — 4.36; 6.62; 3.82; 8.23 mIU/L

Primary: Percent Probability of Pregnancy Among Users of the SILCS Diaphragm Used With Contraceptive Gel Over 6 Months of Typical Use — 12.5; 9.6 percent probability

Primary: Weight — 3.2; 6.8; 7.0 percent weight lost — p=<0.05

Primary: Follicle-stimulating Hormone — 5.01; 5.86; 6.38 milli international units per milliliter — p=0.88

Primary: Continuation at 1 Year — 21; 30 participants

Primary: Mean Serum Concentrations of Etonogestrel and Ethinyl Estradiol — 1275; 1240; 21.9; 14.8 ng/L

Primary: The Cumulative Probability of Typical-use 6 Month (183 Days) Pregnancy. — 0.12; 0.12 6 month probability of pregnancy

Primary: Self-reported Uptake of Effective Ongoing Contraception (Not Condoms) — 5; 13; 22; 0 participants — p=<0.001